Ticlopidine-induced aplastic anemia: development of chromosomal abnormalities and response to immunosuppressive therapy

Am J Hematol. 2000 Mar;63(3):141-4. doi: 10.1002/(sici)1096-8652(200003)63:3<141::aid-ajh6>3.0.co;2-t.

Abstract

Severe aplastic anemia is a well-recognized complication of ticlopidine therapy that carries a high mortality. Therapy with colony-stimulating factors or corticosteroids has been largely ineffective in this disorder. We report a case of ticlopidine-induced aplastic anemia that was successfully treated with cyclosporine and high-dose dexamethasone. The patient rapidly responded to immunosuppressive therapy and had a normal hemogram after cessation of immunosuppression. On long-term follow-up, the patient developed a progressive macrocytic anemia. Repeat bone marrow evaluation demonstrated myelodysplasia with erythroid hypoplasia. An associated chromosomal abnormality consisting of a t(3;16) (q21; p13.3) translocation was detected. This is the first report of a chromosomal abnormality associated with ticlopidine induced marrow aplastic anemia.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anemia, Aplastic / chemically induced*
  • Anemia, Aplastic / drug therapy*
  • Anemia, Aplastic / genetics
  • Bone Marrow / drug effects*
  • Chromosome Aberrations / chemically induced*
  • Chromosome Aberrations / drug therapy*
  • Chromosome Disorders
  • Cyclosporine / therapeutic use
  • Dexamethasone / therapeutic use
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Platelet Aggregation Inhibitors / adverse effects
  • Ticlopidine / adverse effects*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Immunosuppressive Agents
  • Platelet Aggregation Inhibitors
  • Dexamethasone
  • Cyclosporine
  • Ticlopidine